In Silico Design of Dual-Binding Site Anti-Cholinesterase Phytochemical Heterodimers as Treatment Options for Alzheimer’s Disease

Amat-Ur-rasool, Hafsa; Ahmed, Mehboob; Hasnain, Shahida; Ahmed, Abrar; Carter, Wayne Grant

Abstract

The number of patients with neurodegenerative diseases, particularly Alzheimer’s disease (AD), continues to grow yearly. Cholinesterase inhibitors (ChEIs) represent the first-line symptomatic drug treatment for mild-to-moderate AD; however, there is an unmet need to produce ChEIs with improved efficacy and reduced side effects. Herein, phytochemicals with reported anti-acetylcholinesterase (AChE) activity were ranked in silico for their anti-AChE potential. Ligands with a similar or higher binding affinity to AChE than galantamine were then selected for the design of novel dual-binding site heterodimeric drugs. In silico molecular docking of heterodimers with the target enzymes, AChE and butyrylcholinesterase (BuChE), were performed, and anti-cholinesterase binding affinities were compared with donepezil. Drug-likeliness properties and toxicity of the heterodimers were assessed using the SwissADME and ProTox-II webservers. Nine phytochemicals displayed similar or higher binding affinities to AChE than galantamine: sanguinarine > huperzine A > chelerythrine > yohimbine > berberine > berberastine > naringenin > akuammicine > carvone. Eleven heterodimeric ligands were designed with phytochemicals separated by four- or five-carbon alkyl-linkers. All heterodimers were theoretically potent AChE and BuChE dual-binding site inhibitors, with the highest affinity achieved with huperzine-4C-naringenin, which displayed 34% and 26% improved affinity to AChE and BuChE, respectively, then the potent ChEI drug, donepezil. Computational pharmacokinetic and pharmacodynamic screening suggested that phytochemical heterodimers would display useful gastrointestinal absorption and with relatively low predicted toxicity. Collectively, the present study suggests that phytochemicals could be garnered for the provision of novel ChEIs with enhanced drug efficacy and low toxicity.

• Journal Article Type: Article
• Acceptance Date: Dec 27, 2021
• Online Publication Date: Dec 29, 2021
• Publication Date: Jan 1, 2022
• Deposit Date: Jan 10, 2022
• Publicly Available Date: Jan 10, 2022
• Journal: Current Issues in Molecular Biology
• Print ISSN: 1467-3037
• Electronic ISSN: 1467-3045
• Publisher: MDPI AG
• Peer Reviewed: Peer Reviewed
• Volume: 44
• Issue: 1
• Pages: 152-175
• DOI: https://doi.org/10.3390/cimb44010012
• Keywords: Microbiology (medical); Molecular Biology; General Medicine; Microbiology
• Public URL: https://nottingham-repository.worktribe.com/output/7220226
• Publisher URL: https://www.mdpi.com/1467-3045/44/1/12